secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cencora, Inc. (COR)
CIK:        0001140859
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-120852
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B
--------------------------------------------------------------------------------

- Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.
- Acquisition expected to close by end of fiscal Q2 2026, subject to regulatory approvals.
- Cencora paused share repurchases; FY2026 adjusted EPS guidance reiterated but likely lower half of $17.45-$17.75.
- Long-term guidance raised: adjusted operating income growth 7-10%, adjusted EPS growth 10-14%.
- Financing via new debt; $4.5B bridge financing committed; committed to investment grade ratings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1140859/000110465925120852/0001104659-25-120852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1140859/000110465925120852/tm2533461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-120852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer